Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review

Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review

  • Products Id :- GDME363FSA
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Vericel Corp (VCEL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. The company is also developing ixmyelocel-T technology, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. The company sells its products through cell therapy specialists. Vericel is headquartered in Cambridge, the US.

Vericel Corp Key Recent Developments

Aug 20,2018: Vericel names Jonathan Hopper as chief medical officer

Aug 06,2018: Vericel Reports Record Second Quarter Revenues of USD 19.0 Million and Raises Full Year 2018 Revenue Guidance

May 08,2018: Vericel Reports First Quarter 2018 Financial Results

Mar 05,2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance

Feb 14,2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Vericel Corp-Key Facts 6

Vericel Corp-Key Employees 7

Vericel Corp-Key Employee Biographies 8

Vericel Corp-Major Products and Services 9

Vericel Corp-History 10

Vericel Corp-Company Statement 12

Vericel Corp-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Company Overview 14

Vericel Corp-Business Description 15

Product Category: License Revenue 15

Overview 15

Performance 15

Product Category: MACI 15

Overview 15

Product Category: Carticel and MACI 15

Performance 15

Product Category: Epicel 15

Overview 15

Performance 16

R&D Overview 16

Vericel Corp-Corporate Strategy 17

Vericel Corp-SWOT Analysis 18

SWOT Analysis-Overview 18

Vericel Corp-Strengths 18

Vericel Corp-Weaknesses 19

Vericel Corp-Opportunities 20

Vericel Corp-Threats 21

Vericel Corp-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 29

Vericel Corp, Medical Equipment, Deals By Type, 2012 to YTD 2018 30

Vericel Corp, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Aug 20, 2018: Vericel names Jonathan Hopper as chief medical officer 32

Aug 06, 2018: Vericel Reports Record Second Quarter Revenues of USD 19.0 Million and Raises Full Year 2018 Revenue Guidance 33

May 08, 2018: Vericel Reports First Quarter 2018 Financial Results 35

Mar 05, 2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance 37

Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 39

Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 40

May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 42

Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 44

Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 45

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Vericel Corp, Performance Chart (2013-2017) 26

Vericel Corp, Ratio Charts 28

Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 29

Vericel Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 30

List of Tables

Vericel Corp, Key Facts 6

Vericel Corp, Key Employees 7

Vericel Corp, Key Employee Biographies 8

Vericel Corp, Major Products and Services 9

Vericel Corp, History 10

Vericel Corp, Other Locations 13

Vericel Corp, Subsidiaries 13

Vericel Corp, Key Competitors 22

Vericel Corp, Ratios based on current share price 23

Vericel Corp, Annual Ratios 24

Vericel Corp, Annual Ratios (Cont...1) 25

Vericel Corp, Interim Ratios 27

Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 29

Vericel Corp, Medical Equipment, Deals By Type, 2012 to YTD 2018 30

Vericel Corp, Recent Deals Summary 31

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Zimmer Inc

TiGenix Inc

Miltenyi Biotec Inc

Geistlich Pharma North America Inc

Cytori Therapeutics Inc

Compass Biomedical Inc

Avita Medical Americas LLC

Astellas Institute for Regenerative Medicine

Vericel Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8750
Site License
USD 250 INR 17500
Corporate User License
USD 375 INR 26250



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]